Dingxiao Zhang
Assistant Professor
Department of Pharmacology & Therapeutics
Roswell Park Cancer Institute
United States of America
Biography
Dr. Zhang joined the RPCI faculty in 2016. He graduated from Chungbuk National University with a PhD degree in Molecular Embryology from one of the National research laboratories in South Korea. During his doctoral studies, he worked extensively on early embryo development and regulation of maternal gene expression, which led to 8 important publications (4 of which were first author papers) in the field. After finishing Ph.D studies, he did a short post-doctoral training at the University of Cincinnati College of Medicine, studying the role of MED1 and ARGLU1 in breast cancer, with a first author J. Biol. Chem. paper. He then joined MD Anderson Cancer Center as a postdoctoral fellow in February 2012. During his postdoctoral training at MDACC, he has published 8 papers (4 of which were first author papers). He was appointed to an Instructor position in 2015, and an Assistant Professor of Oncology in 2016. Currently, he is using genetic mouse models, cancer cell lines and xenografts, as well as human primary tumor samples to investigate the prostate development (epithelial biology) and prostate tumorigenesis and progression.
Research Interest
Stem cell and cancer stem cells, Cancer cell heterogeneity, Epigenetics and lncRNAs, Prostate and Breast cancer, Nuclear receptors in steroid hormone-regulated cancers
Publications
-
Zhang D, Park D, Zhong Y, Lu Y, Gong S, et al. (2016) Stem cell and neurogenic gene expression profiles link prostate basal cells to aggressive prostate cancer. Nature Communications 7: 10798
-
Zhang D, Lin K, Lu Y, Rycaj K, Zhong Y, et al. (2016) Developing a Novel Two-Dimensional Culture System to Enrich Human Prostate Luminal Progenitors That Can Function as a Cell of Origin for Prostate Cancer. Stem Cells Translational Medicine 5: 1-13
-
Liu C, Liu R, Zhang D, Deng Q, Liu B, et al. (2017) MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nature Communications 8: 14270